Basic Information
| LncRNA/CircRNA Name | circCDR1as |
| Synonyms | circCDR1T, circciRS_7 |
| Region | |
| Ensemble | |
| Refseq |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | cholangiocarcinoma |
| ICD-0-3 | NA |
| Methods | qPCR, other |
| Sample | Cholangiocarcinoma tissues |
| Expression Pattern | up-regulated |
| Function Description | The expression of circRNA Cdr1as in tumor tissues was higher than that in adjacent normal tissues. The overexpression of Cdr1as was closely associated with the advanced TNM stage, lymph node invasion, and postoperative recurrence. The overall survival of CCA patients with high Cdr1as expression was worse than that of the CCA patients with low Cdr1as expression. According to multivariate analysis, the Cdr1as expression could be considered as an independent prognostic biomarker for cholangiocarcinoma with acceptable sensitivity and specificity. |
| Pubmed ID | 29424892 |
| Year | 2018 |
| Title | A Novel Prognostic Biomarker for Cholangiocarcinoma: circRNA Cdr1as |
External Links
| Links for circCDR1as | GenBank HGNC NONCODE |
| Links for cholangiocarcinoma | OMIM COSMIC |